Molecular Medicine

, Volume 10, Issue 1–6, pp 28–35 | Cite as

Angiotensin II-Mediated Endothelial Dysfunction: Role of Poly(ADP-ribose) Polymerase Activation

  • Csaba Szabó
  • Pál Pacher
  • Zsuzsanna Zsengellér
  • Anne Vaslin
  • Katalin Komjáti
  • Rita Benkö
  • Min Chen
  • Jon G. Mabley
  • Márk Kollai


Angiotensin ll (AII) contributes to the pathogenesis of many cardiovascular disorders. Oxidant-mediated activation of poly(adenosine diphosphate-ribose) polymerase (PARP) plays a role in the development of endothelial dysfunction and the pathogenesis of various cardiovascular diseases. We have investigated whether activation of the nuclear enzyme PARP contributes to the development of AII-induced endothelial dysfunction. AII in cultured endothelial cells induced DNA single-strand breakage and dose-dependently activated PARP, which was inhibited by the AII subtype 1 receptor antagonist, losartan; the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, apocynin; and the nitric oxide synthase inhibitor, N-nitro-l-arginine methyl ester. Infusion of sub-pressor doses of AII to rats for 7 to 14 d induced the development of endothelial dysfunction ex vivo. The PARP inhibitors PJ34 or INO-1001 prevented the development of the endothelial dysfunction and restored normal endothelial function. Similarly, PARP-deficient mice infused with AII for 7 d were found resistant to the AII-induced development of endothelial dysfunction, as opposed to the wild-type controls. In spontaneously hypertensive rats there was marked PARP activation in the aorta, heart, and kidney. The endothelial dysfunction, the cardiovascular alterations and the activation of PARP were prevented by the angiotensin-converting enzyme inhibitor enalapril. We conclude that AII, via AII receptor subtype 1 activation and reactive oxygen and nitrogen species generation, triggers DNA breakage, which activates PARP in the vascular endothelium, leading to the development of endothelial dysfunction in hypertension.



This work was supported by grants from the National Institutes of Health (R01 HL59266) to CS and by a grant from the Hungarian Research Fund (OTKA T047095). Dr Pacher is on leave from the Institute of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. CS and PP contributed equally to this work. The expert technical assistance of Ms L Cannastra is appreciated.


  1. 1.
    Virag L, Szabo C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54:375–429.CrossRefGoogle Scholar
  2. 2.
    Hassa PO, Hottiger MO. (2002) The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol.Life Sci. 59:1534–53.CrossRefGoogle Scholar
  3. 3.
    Drexler H, Hornig B. (1999) Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 31:51–60.CrossRefGoogle Scholar
  4. 4.
    Wolf G. (2000) Free radical production and angiotensin. Curr. Hypertens. Rep. 2:167–73.CrossRefGoogle Scholar
  5. 5.
    Singh BM, Mehta JL. (2003) lnteractions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch. Intern. Med. 163:1296–304.CrossRefGoogle Scholar
  6. 6.
    Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. (2003) The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet. Med. 20:607–21.CrossRefGoogle Scholar
  7. 7.
    Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. (1997) Role of superoxide in angiotensin ll-induced but not catecholamine-induced hypertension. Circulation 95:588–93.CrossRefGoogle Scholar
  8. 8.
    Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego Conde LJ, Umans JG, Wilcox CS. (2003) Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin ll of afferent arterioles from rabbits infused with angiotensin II. J. Am. Soc. Nephrol. 14:2783–9.CrossRefGoogle Scholar
  9. 9.
    Rueckschloss U, Duerrschmidt N, Morawietz H. (2003) NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid. Redox. Signal. 5:171–80.CrossRefGoogle Scholar
  10. 10.
    Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511–5.CrossRefGoogle Scholar
  11. 11.
    Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. (2000) Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J. 14:271–8.CrossRefGoogle Scholar
  12. 12.
    Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA. (2003) Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem. Pharmacol. 65:1189–97.CrossRefGoogle Scholar
  13. 13.
    Jagtap P et al. (2002) Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit. Care Med. 30:1071–82.CrossRefGoogle Scholar
  14. 14.
    Garcia Soriano F et al. (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 7:108–13.CrossRefGoogle Scholar
  15. 15.
    Shimoda K et al. (2003) Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 285:240–9.CrossRefGoogle Scholar
  16. 16.
    Khan TA et al. (2003) Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J. Am. Coll. Surg. 197:270–7.CrossRefGoogle Scholar
  17. 17.
    Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C. (2002) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J. Am. Coll. Cardiol. 40:1006–16.CrossRefGoogle Scholar
  18. 18.
    Pacher P et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896–904.CrossRefGoogle Scholar
  19. 19.
    Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabo C. (2002) Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med. 9:659–64.PubMedGoogle Scholar
  20. 20.
    Szabo C, Cuzzocrea S, Zingarelli B, O’Connor M, Salzman AL. (1997) Endothelial dysfunction in a rat model of endotoxic shock. lmportance of the activation of poly(ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100:723–35.CrossRefGoogle Scholar
  21. 21.
    Cuzzocrea S et al. (1997) Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br. J. Pharmacol. 121:1065–74.CrossRefGoogle Scholar
  22. 22.
    Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. (2001) Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89:684–91.CrossRefGoogle Scholar
  23. 23.
    Zhang H et al. (1999) Angiotensin ll-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 44:215–22.CrossRefGoogle Scholar
  24. 24.
    Pueyo ME et al. (2000) Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20:645–51.CrossRefGoogle Scholar
  25. 25.
    Mervaala EM et al. (2001) Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37:414–8.CrossRefGoogle Scholar
  26. 26.
    Cai H et al. (2002) NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J. Biol. Chem. 277:48311–7.CrossRefGoogle Scholar
  27. 27.
    Mollnau H et al. (2002) Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90:58–65.CrossRefGoogle Scholar
  28. 28.
    Goto K, Fujii K, Onaka U, Abe I, Fujishima M. (2000) Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 36:575–80.CrossRefGoogle Scholar
  29. 29.
    Raasch W et al. (2002) Regression of ventricular and vascular hypertrophy: are there differences between structurally different ACE inhibitors? J. Hypertens. 20:2495–504.CrossRefGoogle Scholar
  30. 30.
    Ji Y, Huang Y, Han Y, Xu Y, Ferro A. (2003) Cardiac effects of amiloride and of enalapril in the spontaneously hypertensive rat. J Hypertens. 21:1583–9.CrossRefGoogle Scholar
  31. 31.
    Go YM et al. (1999) Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. Am. J. Physiol. 277:1647–53.Google Scholar
  32. 32.
    Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D. (2001) Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 38:1162–6.CrossRefGoogle Scholar
  33. 33.
    Fleming l, Busse R. (2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:1–12.CrossRefGoogle Scholar
  34. 34.
    Tham DM et al. (2002) Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 11:21–30.CrossRefGoogle Scholar
  35. 35.
    Costanzo A et al. (2003) Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J. Cell. Physiol. 195:402–10.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2004

Authors and Affiliations

  • Csaba Szabó
    • 1
    • 2
  • Pál Pacher
    • 1
  • Zsuzsanna Zsengellér
    • 1
  • Anne Vaslin
    • 1
  • Katalin Komjáti
    • 1
    • 2
  • Rita Benkö
    • 1
    • 2
  • Min Chen
    • 1
  • Jon G. Mabley
    • 1
  • Márk Kollai
    • 2
  1. 1.Inotek Pharmaceuticals CorporationBeverlyUSA
  2. 2.Institute of Human Physiology and Clinical Experimental ResearchSemmelweis University Medical SchoolBudapestHungary

Personalised recommendations